GlaxoSmithKline and XenoPort Submit Supplemental New Drug Application to FDA for Horizant™ in Postherpetic Neuralgia

GlaxoSmithKline GSK and XenoPort, Inc. XNPT announced today that a supplemental New Drug Application has been submitted to the U.S. Food and Drug Administration requesting approval of Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia in adults. The sNDA has been submitted to the FDA by GSK.